Biomed Israel 2024’s Post

#BiomedIsrael continues to be the largest and most recognized platform in the life science industry. Dear friends & colleagues While the path may be fraught with challenges, our objectives remain unaltered: to create a space where ideas thrive, interpersonal connections flourish, and inspiration leads the way. In times of uncertainty, our determination to collaborate and solve global unmet needs serves as a beacon of hope and becomes our greatest strength. Read more >> https://bit.ly/3O8KroH Don’t miss this fantastic opportunity for maximum exposure and build lasting business opportunities! Exhibit at Biomed Israel 2024 ♦ Showcase Your Product/Technology in the Exhibition Area ♦ Generate New Leads ♦ Enhance Current Business Endeavors ♦ Gain Unlimited Potential for New Business Ventures ♦ Benefit from Marketing Targeted to the Industry's Audience ♦ Company Profile Featured on the Biomed Website and Conference related materials #BiomedIsreal #StartUp #Biomedical #AI #BioConvergence #BioFood #GeneTherapy #Robotics #DigitalHealth #InfectiousDisease #MedicalDevice #B2B #intercontinental

Michel Cheron, President and CEO of Laboratoires Vivacy, invites all #startups and big names in the injectables industry to join the Medical Aesthetic Injectable Summit (MAIS) on October 4 & 5, 2024 in Marbella, Spain. MAIS brings together prominent figures from the different sectors of the injectables market in one location - KOL physicians, top academics, industry executives, and visionary entrepreneurs - to discuss the entire ecosystem of injectables, from toxins, HA, and injecting tools to AI, robotics, and more! It's the first of its kind, where the leaders and the labs get together to delve into the science behind products, market data, disruptive technologies, and regulations, to drive the future of injectables. 📔 Take a look at the full program: https://lnkd.in/grhSr5sP 🐣 Register with Early Bird rates: https://lnkd.in/g8PPNhGc 👉 Looking to sponsor? Find details here: https://lnkd.in/g__9qNPD

Owkin , the first end-to-end AI biotech unicorn offering world-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland). After partnering with nine of the region's leading centers, including Charité - Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital Basel, Technical University of Munich (TUM), University Hospital Erlangen, University Hospital Leipzig, Insel Gruppe in Bern, University Hospital Mannheim-Heidelberg and Medical University of Vienna. These collaborations represent an unprecedented representation of patient populations, covering 24% of all outpatient cases and 15% of all patients in the DACH region. Guillaume Bézie, Director of Partnerships in Western Europe: “The Western European network, which includes France, the Benelux countries and the DACH region, forms the largest pool of centers for Owkin. Our collaboration with leading academic institutions has irreplaceable value for our expansion strategy. By involving patients from different backgrounds for different diseases, we can use our AI to better respond to the unique needs of each individual. Together with our partners, we are fully dedicated to accelerating the use of secondary benefits of #multimodal patient data to provide the right treatment to each patient.” Philipp Mann, Venkat Sethuraman, Yedidia Levy-Zauberman, Thomas Bonnotte, Ph.D., MS, Pierre-Antoine Bannier, Philip Conti-Permanne To share your startup story write us on - contact@startuprise.co.uk #Owkin #biotech #AI #Unicorn #development #news #startup

Data and Artificial Intelligence (AI) have the potential to reshape the entire life sciences value chain and healthtech delivery paradigm. BioAsia 2024 is 26-28 February in Hyderabad and this year’s event will explore the potential opportunities that data and AI can unleash for life sciences companies, and the possibility of reshaping the future of healthtech delivery paradigm. ✓ Life sciences ✓ Healthtech ✓ AI-driven technologies ✓ Drug-discovery and development If you are attending BioAsia 2024 and would like to discuss global talent within Life Sciences & Pharma, our founder, Gayatri Shah, will be at the event. #BioAsia2024 #LifeSciences #DrugDiscovery #DrugDevelopment #HealthTech #Pharma #ExecutiveSearch

🌐 Efficient and AI-Driven Precision in Drug Development: A Key Reason to Partner with iBio 🚀 At iBio, we're transforming the landscape of drug development through our innovative AI-driven approach. The graphic below highlights the second key reason why partnering with us is a strategic move for success: Efficiency and AI-driven precision drug development. 🔍 Precision Meets Pace - Our cutting-edge AI technologies streamline the development process, ensuring precision and speed. 🧬 Harnessing the Power of AI - Leveraging AI, we accelerate the identification and optimization of therapeutic candidates. 💡 Innovation at the Core - Our commitment to innovation extends beyond our technologies. We continuously evolve our strategies to stay at the forefront of biotech advancements, ensuring our partners benefit from the latest in drug development excellence. Join us in shaping the future of drug development. Partner with iBio for efficient, AI-powered innovation that leads to real-world impact. #iBioInc #DrugDevelopment #Biotechnology #Innovation #Partnership #AI

BIOVOICE MAGAZINE: The Cover story in the March-April 2024 edition tracks the journey of MEDGENOME, the India’s leading genomics solutions company with a promising product portfolio in diagnostics and research services. Featuring exclusive insights by: ♦ Mahesh Pratapneni Co-founder, Group CEO, MedGenome ♦ Vedam Ramprasad, PhD, CEO, MedGenome ♦ SURAJIT CHAKRABARTTY, CFO, MedGenome Follow the link to read the complete issue: https://lnkd.in/gFFx8YZn STARTUP SPECIAL ♦ On a mission to build a comprehensive healthcare ecosystem, MyHealthcare Technologies is playing a pivotal role in standardizing the care delivery process, minimizing medical administration errors, and constructing a centralized patient longitudinal history. Shyatto Raha Aneesh Nair Ph.D Divya Laroyia EXPERT INSIGHTS ♦ Kausik Maiti, MD, Executive Director, Safety Medical Sciences, Parexel India shares insights on the need for closing gaps in clinical trial accessibility. EXPERT INSIGHTS ♦ Ankit Kumar, Founder & CEO, Skye Air Mobility writes on the technology evolution and integration of drones ensuring a prosperous future for the nation’s farmers. EXPERT INSIGHTS ♦ Sat Kumar Tomer, Founder and CEO, Satyukt Analytics explains how integration of IoT and analytics in smart farming, coupled with satellite technology, is shaping the future of agriculture. EXPERT INSIGHTS ♦ Ritwik Bahuguna, Managing Director, Farlense Group writes on the role of Mega Food Parks in transforming the agriculture sector and unlocking its real potential though processing and value addition. Happy Reading! #MedTech #Startups #medicaldevices, #agritech #startups #sustainability #bioscience #biotech #biopharma, #agriculture #medtech #diagnostics #healthcare #digital #AI #MachineLearning #ML #Bigdata #precisionmedicine #blockchain #RahulKoul #interview #insights #experts #magazine #news #India 

@Artificial Intelligence, Deep Learning, Machine Learning

Wednesday July 24th, 8-9.30am PT. USA-UK-ANGELS: https://lnkd.in/gvjDPmkU A collection of British linked startups, either based in UK or by British educated or UK citizen founders. 8:10 - 8:25 AlgoDynamix: AlgoDynamix is a pioneer of behavioural-based price forecasting for the financial markets. 8:25-8:40 Lúnasa Space: Lúnasa is building enabling technologies for space infrastructure services, and in-space testbeds 8:40 - 8:55 Ani Biome: Ani Biome developed a machine learning architecture for non-invasive digital diagnostics and personalization of liquid fermented bioactives, AgeBiotics. 8:55 - 9:10 Oxford Drug Design: Oxford is a pre clinical therapeutics with distinctive GenAI drug discovery platform (SynthAI) overcomes inefficiency limitations of current methods and accelerates the potential impact for patients.

61% of #DeSci projects are in the healthcare sector. That's where DeSci is already making a splash — in longevity, genomics, pharma, and other highly specialized fields. Here’s a look at some of the standout projects: 🧬 Molecule AG, a DeSci funding platform, which now has over 250 research projects listed, more than 4,500 DAO community members, and over $30M in ecosystem funds. The platform enables researchers and investors to govern and own research-related intellectual property (IP) directly. 🔬 Hippocrat, a project that leverages decentralized health data, collaborated with SolveCare Korea, another healthcare startup. SolveCare introduced Hippocrat's blockchain-based telemedicine solution to the Korean market and is exploring joint research and development opportunities. Hippocrat also launched a research bounty program on ResearchHub. The goal is to identify underserved populations and regions where Hippocrat's AI-powered telemedicine application could bridge the healthcare accessibility gap. 💾 Galeon is a project focused on electronic health records (EHR) and medical AI. It recently announced a partnership with HCS Pharma, a healthcare company focused on medical research and drug development. The collaboration aims to connect hospitals through a shared patient record system developed by Galeon, enabling structured data collection and utilization for medical research and new treatment discovery. 🌱 VitaDAO, a prominent DeSci project known for longevity research, received $12.7mil in its 2022 round of funding from investors, including #biotech giant NorthPond Ventures. In 2023, it obtained further funding from Pfizer Ventures, making Pfizer the first pharmaceutical company to vote on a DAO proposal. In turn, VitaDAO has been able to allocate funding to various research projects, with the first being a longevity research project by Scheibye-Knudsen Lab in Denmark. 🔎 Explore other exciting DeSci projects and their business models in our latest research report: https://lnkd.in/dgjcEzS8 #DecentralizedScience #Healthcare